Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine

NCT00103467 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of Anthrax Infection

Interventions

BIOLOGICAL: rPA102 Vaccine

Sponsor

VaxGen